Ro and WeightWatchers Clinic now carry brand only
Two of the largest consumer platforms stopped selling compounded tirzepatide during 2026, with membership billed separately from medication.
Two of the largest consumer platforms stopped selling compounded tirzepatide during 2026, with membership billed separately from medication.
For context: across 32 tracked tirzepatide telehealth programmes, 17 publish a price we could capture, and the cheapest verified all-in cost is $215 a month at a 10 mg maintenance dose — about $2,580 for a first year. Compounded preparations are not FDA-approved. Prices captured 2026-08-05.
All-in monthly cost at 10 mg
Multiple named provider round-ups dated August 2026 report Ro and the WeightWatchers clinic carrying brand-name products only. Calibrate operates a brand-only membership model and Noom's published figures describe brand Zepbound.
Any list still ranking those companies for compounded tirzepatide is describing a product they no longer sell. Check its verification date.
The cheap end of the market is now served by smaller operators with little brand recognition, which raises the value of verifying the pharmacy rather than trusting the name.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.
The cheapest verified compounded route we track currently sits at $215 a month all-in at a 10 mg maintenance dose, about $2,580 for a first year. Where a development moves that figure, our tables move with it on the next build.
How to verify this yourself
Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.
Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.
How to read a market story in this market
Market stories change who is selling rather than what the medicine does, and they land on patients at renewal rather than in advance.
The practical exposure is to programmes you cannot easily replace. Long prepaid terms with a programme whose pharmacy you cannot identify are the worst combination, because both the money and the supply chain are opaque at the moment you need them not to be.
What this does not change
The prescription requirement, the licensing framework behind a dispensing pharmacy, and the clinical review that should sit in front of any prescription. Those are stable and none of the developments we track has altered them.
It also does not change the arithmetic of choosing a programme: price the dose you expect to hold, add every recurring fee, and verify the pharmacy. The cheapest verified route we track is NexLife at $215 a month all-in at a maintenance dose, about $2,580 for a first year.
Where a development does move those figures, the tables regenerate from the dataset on the next build rather than being edited by hand.
When urgency is the product
Regulatory and market news is routinely used as a sales device. A programme citing a rule change to push you into a twelve-month prepayment is using a real fact to manufacture a deadline that does not apply to you.
The test is simple: does the development change what you can lawfully be prescribed this month? Almost never. Does it change what you should pay? Sometimes. Does it require you to decide today? Essentially never — and a programme insisting otherwise has told you how it treats its patients under commercial pressure.
Where market sits in the decision
Most people arrive at this market with one question — what is cheapest — and leave with a worse one, because cheapest depends on a dose nobody has chosen yet and a fee structure that is not in the advertisement.
6 of the 17 priced programmes charge a mandatory recurring fee on top of medication. 11 hold one price at every strength; the rest reprice as you climb. Those two facts reorder any ranking built on headline figures, and neither is visible without reading the terms.
The four disclosures worth insisting on
Price at the dose you will hold. The identity of the dispensing pharmacy. Whether the quoted rate survives renewal. And what is refundable before shipment.
Only 3 of 17 priced programmes publish the second, which is the one that lets you check a public state board register before injecting anything weekly. It costs a programme nothing to publish and its absence is the most reliable signal in this market.
Turning this into an email
Everything above converts into questions a programme can answer in two minutes. Anything that cannot is context rather than a check, and context does not protect you.
Send them before paying. Almost every dispute that appears in public complaint records for this category traces to a number that was never put in writing, and the programmes that reply promptly and specifically are rarely the ones patients later write about.
The failure mode this section is guarding against
Choosing a programme on a number that describes a different situation than yours. An entry price when you will hold maintenance. A medication figure when a membership applies. A promotional rate when you will renew. A prepaid rate when you will pay monthly.
Each of those errors is small individually and they compound in the same direction, which is why the cheapest-looking option in most published comparisons is the one most likely to be mis-stated.
Priced correctly, the cheapest verified route sits at $215 a month all-in at a maintenance dose. Anything materially below that band deserves the question of which distortion is producing it.
Why we publish the working rather than a verdict
A single recommendation is more useful to read and less useful to act on, because it hides the weighting. Two readers with different maintenance doses, different coverage and different tolerance for commitment should not receive the same answer.
So the tables carry the inputs and the rankings state their sort key. If you disagree with our weighting, take the file and weight it differently — that is what publishing it is for.
What would make this page wrong
A price change we have not captured, a programme leaving the market, or a figure we recorded from a third party that does not survive checking. All three have happened during 2026 and all three are logged when they do.
Prices here were captured 2026-08-05. Treat anything older than a month as needing a re-check against the provider's own page, which every programme record links directly.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.